Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Rubius Therapeutics Inc (RUBY)

Rubius Therapeutics Inc (RUBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cellarity Announces Close of $121 Million Series C Financing

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 31.96 (+1.95%)
EVLO : 0.9700 (+6.62%)
FHTX : 8.15 (+0.99%)
MRNA : 171.06 (+0.46%)
OMGA : 6.29 (-6.26%)
RUBY : 0.2600 (-22.89%)
SANA : 4.76 (+0.85%)
MCRB : 5.44 (-0.91%)
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping...

DNLI : 31.96 (+1.95%)
EVLO : 0.9700 (+6.62%)
FHTX : 8.15 (+0.99%)
MRNA : 171.06 (+0.46%)
OMGA : 6.29 (-6.26%)
RUBY : 0.2600 (-22.89%)
SANA : 4.76 (+0.85%)
MCRB : 5.44 (-0.91%)
Rubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?

Rubius Therapeutics, Inc. (RUBY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

RUBY : 0.2600 (-22.89%)
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial...

RUBY : 0.2600 (-22.89%)
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.2600 (-22.89%)
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

/PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the...

RUBY : 0.2600 (-22.89%)
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting

Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens...

RUBY : 0.2600 (-22.89%)
Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer

Flagship Pioneering, the bioplatform innovation company, and Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined...

DNLI : 31.96 (+1.95%)
EVLO : 0.9700 (+6.62%)
FHTX : 8.15 (+0.99%)
MRNA : 171.06 (+0.46%)
OMGA : 6.29 (-6.26%)
RUBY : 0.2600 (-22.89%)
SANA : 4.76 (+0.85%)
MCRB : 5.44 (-0.91%)
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.2600 (-22.89%)
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.2600 (-22.89%)

Barchart Exclusives

10-Year Treasury Notes: Higher or Lower Rates to Come?
With the March Treasury futures, First Notice Day (FND), arriving on the last day of February, a significant seasonal pattern may impact the current uptrend. Add the explosive employment number, and the interest rate market is ripe for a correction. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar